ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2614

Single Academic Center Experience with 14-3-3 Eta in the Evaluation of Inflammatory Arthritis

Lance Feller1, Paul Tuttle IV2, Austin M. Dalrymple3, Srikanth Bathula4, Katherine Temprano5, Reema H. Syed6, Rama Bandlamudi7, Kathryn Coulson8, Peri Pepmueller9 and Terry Moore10, 1Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO, 2Saint Louis University, Saint Louis, MO, 3Pediatric Rheumatology, St. Louis University, St. Louis, MO, 4Rheumatology, Saint Louis University, Saint Louis, MO, 5Medicine/Rheumatology, Saint Louis University, St. Louis, MO, 6IM-Rheumatology, Saint Louis University, St. Louis, MO, 7Internal Medicine/Rheumatology, St. Louis Univ Health Sciences, St. Louis, MO, 8Rheumatology/ 213A, St. Louis University, St. Louis, MO, 9Rheumatology, Saint Louis University, St. Louis, MO, 10Division of Rheumatology and Pediatric Rheumatology, Saint Louis University School of Medicine, St Louis, MO

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, Diagnostic Tests, Inflammatory arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription regulation. Among their targets are phosphatases, kinases and transmembrane receptors. There are seven known isoforms in mammals. The η (Eta) isoform has been implicated as having diagnostic potential in inflammatory arthritis. In this study we investigated the utility of measuring 14-3-3η when evaluating inflammatory arthritis.

Methods:

Measurements of 14-3-3η were obtained during evaluation of joint pain in patients presenting between July 2013 and April of 2015. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP Ab) were measured. Joint imaging was evaluated for erosive changes and use of biologics was recorded. A chart review was later conducted to evaluate the utility of standard measures versus 14-3-3η.

Results:

214 patients were evaluated. 49 had a diagnosis of rheumatoid arthritis (RA), 17 had psoriatic arthritis (PsA). 43 patients had connective tissue disease (CTD), 8 had undifferentiated inflammatory arthritis, and 97 had other rheumatological disorders.

Of the 49 RA patients, 37 were RF positive, 36 were anti-CCP Ab positive, and 25 were 14-3-3η positive. Of the 25 who were 14-3-3η positive, 22 were both anti-CCP Ab and RF positive, 2 were RF positive but anti-CCP Ab neg, and 1 was negative for both RF and anti-CCP Ab.  Of the 24 who were 14-3-3η negative, 12 were both RF and anti-CCP Ab positive, 2 were only anti-CCP Ab positive, 1 was only RF positive, and 9 were seronegative. 20 patients in total had erosive disease of which 13 were positive for 14-3-3η, 10 were positive for all three markers, 1 was positive for just RF, and 1 was negative for both RF and anti-CCP Ab. Of the RA patients with erosive changes on biologic medication, 5 were 14-3-3η positive and 8 were 14-3-3η negative.

All 17 patients with PsA were seronegative with one exception, who was 14-3-3η positive. 6 PsA patients had joint erosions and they were seronegative. Of the 43 patients with CTD, 6 were 14-3-3η positive. 2 patients had enteropathic arthritis and were seronegative.

14.3.3η alone

RF and CCP

Triple Positive

14.3.3η and RF

14.3.3η and CCP

Any seropositivity

RA sensitivity

0.51

0.69

0.45

0.49

0.45

0.82

RA specificity

0.90

0.97

0.98

0.94

0.98

0.79

RA PPV

0.49

0.50

0.50

0.50

0.50

0.49

RA NPV

0.88

0.92

0.86

0.87

0.86

0.95

Conclusion:

The 14-3-3η protein can be detected in inflammatory arthritis, with the highest percentage in RA patients. However, there was no correlation between 14-3-3η titers with RF or anti-CCP Ab. No significant association was found with PsA patients in our small sample.  There was also no correlation with biologic use.  One 14-3-3η positive patient who was negative for RF and anti-CCP Ab had erosive disease.


Disclosure: L. Feller, None; P. Tuttle IV, None; A. M. Dalrymple, None; S. Bathula, None; K. Temprano, None; R. H. Syed, None; R. Bandlamudi, None; K. Coulson, None; P. Pepmueller, None; T. Moore, None.

To cite this abstract in AMA style:

Feller L, Tuttle P IV, Dalrymple AM, Bathula S, Temprano K, Syed RH, Bandlamudi R, Coulson K, Pepmueller P, Moore T. Single Academic Center Experience with 14-3-3 Eta in the Evaluation of Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/single-academic-center-experience-with-14-3-3-eta-in-the-evaluation-of-inflammatory-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/single-academic-center-experience-with-14-3-3-eta-in-the-evaluation-of-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology